Trial Profile
A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors CoLucid Pharmaceuticals; Eli Lilly and Company
- 02 Sep 2021 Results of meta-analysis from NCT02439320, NCT00883051, NCT00384774 and NCT02605174; evaluating the efficacy and safety of Lasmiditan for the treatment of acute migraine in adults, published in the Journal of Clinical Pharmacology
- 12 Sep 2020 Results of meta-analysis of 5 studies assessing influence of lasmiditan versus placebo on pain control in patients with migraine, published in the Clinical Neuropharmacology.
- 13 Jan 2020 Results published in the Headache